Spot the chance with global eyes, Meet unmet needs where healing lies.
Biosion's Partner Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052Release time:2025-06-26 11:05:00Nanjing, China, Newark, U.S.A June. 23, 2025-Biosion, a global, clinical-stage biotechnology company, announced that its partner, Aclaris Therapeutics, Inc.
NANJING, China and NEWARK, Del., April 11, 2025-Biosion, Inc. , a global, clinical-stage biotechnology company, today announced that preclinical data for BSI-721, a novel antibody-drug conjugate (ADC) targeting CDH17, will be presented at the upcoming American Association for Cancer Research (AAC
Newark, DE, U.S. and Nanjing, China, Apr. 27, 2025-Biosion, a global clinical-stage biotechnology company, announced that its partner, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) applicat